Vosoritide

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 123 publications

A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.

A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.

Journal: NEJM evidence

Published: September 09, 2026

The Ethics of Growth-Promoting Pharmaceuticals for Achondroplasia.

The Ethics of Growth-Promoting Pharmaceuticals for Achondroplasia.

Journal: The American journal of bioethics : AJOB

Published: September 09, 2026

Retinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia.

Retinal Structural and Microvascular Findings During Novel NPR-B-Targeted Vosoritide Therapy in Children with Achondroplasia.

Journal: Journal of clinical medicine

Published: August 27, 2026

A Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia.

A Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia.

Journal: Cureus

Published: August 17, 2026

Achondroplasia: Current Disease-Modifying Therapies and Genome Editing Strategies.

Achondroplasia: Current Disease-Modifying Therapies and Genome Editing Strategies.

Journal: International journal of molecular sciences

Published: July 29, 2026

Emerging NPR-B agonists for cartilage and bone: from CNP biology to translational compound design.

Emerging NPR-B agonists for cartilage and bone: from CNP biology to translational compound design.

Journal: Frontiers in chemistry

Published: July 27, 2026

Healthcare and Psychosocial Needs in Achondroplasia Across the Lifespan: Developmental Functioning, Multidisciplinary Care, and Family-Centered Outcomes.

Healthcare and Psychosocial Needs in Achondroplasia Across the Lifespan: Developmental Functioning, Multidisciplinary Care, and Family-Centered Outcomes.

Journal: Healthcare (Basel, Switzerland)

Published: July 22, 2026

From FGFR3 Hyperactivation to Disease-Modifying Therapy in Pediatric Achondroplasia: Molecular Mechanisms, Clinical Evidence, and Emerging Treatments.

From FGFR3 Hyperactivation to Disease-Modifying Therapy in Pediatric Achondroplasia: Molecular Mechanisms, Clinical Evidence, and Emerging Treatments.

Journal: Children (Basel, Switzerland)

Published: July 22, 2026

Evaluation of sleep-related breathing disorders and polysomnography findings in pediatric patients with achondroplasia.

Evaluation of sleep-related breathing disorders and polysomnography findings in pediatric patients with achondroplasia.

Journal: European journal of pediatrics

Published: July 17, 2026

Growth plate senescence, chondrocyte biology, and the growth hormone-insulin-like growth factor 1 axis in childhood growth.

Growth plate senescence, chondrocyte biology, and the growth hormone-insulin-like growth factor 1 axis in childhood growth.

Journal: Journal of pediatric endocrinology & metabolism : JPEM

Published: July 08, 2026

Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series.

Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series.

Journal: Hormone research in paediatrics

Published: June 14, 2026

Consensus statement on the management of Achondroplasia in the Middle East.

Consensus statement on the management of Achondroplasia in the Middle East.

Journal: Frontiers in endocrinology

Published: May 22, 2026

Showing 1-12 of 123

Last Updated: 11/08/2026